Search Results - Tim Grob

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome by Adil S.A. Al Hinai, Marta Pratcorona, Tim Grob, François G. Kavelaars, Elena Bussaglia, Mathijs A. Sanders, Josep Nomdedeu, Peter J.M. Valk

    Published in HemaSphere (2019-04-01)
    Get full text
    Article


  2. 2

    FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation by Caroline Engen, Monica Hellesøy, Tim Grob, Adil Al Hinai, Atle Brendehaug, Line Wergeland, Siv Lise Bedringaas, Randi Hovland, Peter J. M. Valk, Bjørn T. Gjertsen

    Published in Molecular Oncology (2021-09-01)
    Get full text
    Article


  3. 3

    Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA by Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk

    Published in HemaSphere (2024-08-01)
    Get full text
    Article


  4. 4

    Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML by Christian M. Vonk, Tim Grob, Melissa Rijken, François G. Kavelaars, Jolinda M. L. Konijnenburg, Gert J. Ossenkoppele, Markus G. Manz, Violaine Havelange, Yngvar Fløisand, Bob Löwenberg, Peter J. M. Valk

    Published in Blood Advances (2025-03-01)
    Get full text
    Article


Search Tools: